Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ExelixisEXEL -1.32%88 Days Payable is 139.62 as of Jun. 2026, which is 18% below its 10-year median of 169.72. GuruFocus rates EXEL with a GF Score™ of 88/100 and a GF Value™ of $45.73 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 703 Biotechnology companies, Exelixis ranks better than 52.49% on this metric.
Exelixis's average Accounts Payable for the
three
months ended in Jun. 2026 was $32 Mil. Exelixis's Cost of Goods Sold for the
three
months ended in Jun. 2026 was $21 Mil.
Hence, Exelixis's Days Payable for the
three
months ended in Jun. 2026 was 139.62.
The historical rank and industry rank for Exelixis's Days Payable or its related term are showing as below:
EXEL'
s Days Payable Range Over the Past 10 Years
Min: 122.72 Med: 169.72 Max: 361.16
Current: 122.72
During the past 13 years, Exelixis's highest Days Payable was 361.16. The lowest was 122.72. And the median was 169.72.
EXEL's Days Payable is ranked better than 52.49% of 703
companies
in the Biotechnology industry
Industry Median: 110.14
vs EXEL: 122.72
Exelixis's Days Payable
declined
from Jun. 2025 (160.90) to Jun. 2026 (139.62).
It may suggest that Exelixisaccelerated paying its suppliers.
The historical data trend for Exelixis's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Exelixis's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exelixis Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exelixis's Days Payable distribution charts can be found below:
* The bar in red indicates where Exelixis's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Exelixis's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exelixis (EXEL) has a Days Payable of 139.62 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Exelixis and its competitors. This is 18% below median its historical median of 169.72. Over the past decade, Exelixis' Days Payable has ranged from 122.72 to 361.16. According to the industry distribution chart, Exelixis ranks #334 out of 703 companies in the Biotechnology industry, placing it in the top 47.5%.
Is Exelixis' Days Payable too high?
Exelixis' current Days Payable of 139.62 is 18% below median its 10-year median of 169.72. Over the past 10 years, this metric has ranged from a low of 122.72 to a high of 361.16. The Biotechnology industry median Days Payable is 110.14. Exelixis' value of 139.62 is 26.8% above this industry median. Based on the distribution chart, Exelixis ranks #334 out of 703 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Exelixis has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exelixis' Days Payable compare to MDGL and AXSM?
According to the Biotechnology industry distribution chart, Exelixis ranks #334 out of 703 companies for Days Payable. This puts Exelixis in the upper half of its industry. The industry median Days Payable is 110.14. Exelixis' value of 139.62 is 26.8% above this benchmark. Historically, Exelixis' own Days Payable has ranged from 122.72 to 361.16 over the past decade. While the company's 10-year median is 169.72 vs. the industry median of 110.14, Exelixis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.14, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Exelixis's current Days Payable of 139.62 is 26.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Exelixis and its competitors. For the Biotechnology industry, the median Days Payable is 110.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Exelixis's current Days Payable is 139.62, which is 18% below median its own 10-year median of 169.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exelixis stock overvalued right now?
Based on GuruFocus' analysis, Exelixis (EXEL) is currently considered Modestly Overvalued. The stock's GF Value™ is $45.73, compared to a current price of $53.68 — trading 17.4% above its estimated fair value. The current Days Payable is 139.62, which is 18% below median its 10-year median of 169.72 and 26.8% above the Biotechnology industry median of 110.14. Exelixis' overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Exelixis (EXEL), the current Days Payable is 139.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Exelixis (EXEL) Overvalued in 2026?
Based on GuruFocus' analysis, Exelixis stock appears to be overvalued.
The current stock price of $53.68 is trading 17.4% above its estimated GF Value™ of $45.73.
GuruFocus considers Exelixis to be Modestly Overvalued.
Key valuation signals for EXEL:
Days Payable: 139.62 (18% below median its 10-year median of 169.72)
GF Value™: $45.73 vs. price of $53.68 (17.4% above fair value)
Industry Position: 26.8% above the Biotechnology median (#334 of 703)
No single metric tells the full story. See the EXEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
88GF Score
Get the complete analysis for EXEL
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EXEL has been successfully added to your 
